Burcon NutraScience Corporation

AI-generated fair value estimate for this company.

Method: Terminal-value revenue-multiple approach (early-stage/development-company method): ~$4M USD FY2026E revenue base (per management's stated calendar-2026 profitability target, built on $1-3M CAD CY2025 revenue guidance and a $6.8M CAD multi-year production agreement); 35% annual revenue growth years 1-5 (commercial ramp of newly-launched Puratein C and pea protein sales); 20% annual growth years 6-10; 3x exit revenue multiple applied to ~$33M Year-10 revenue for terminal enterprise value; 18% discount rate reflecting going-concern and execution risk; ~$5.2M USD pro forma net debt (post upsized $21M CAD convertible debenture and $0.7M CAD loan, net of ~$1.8M CAD cash and ~$7.9M CAD secured loan, converted at 0.73 USD/CAD); 12.69M shares outstanding.

Reasoning: Burcon is a decades-old plant-protein IP licensor only now converting to real commercial sales (783% YoY quarterly revenue growth off a tiny base) while carrying negative book equity (-$5.8M CAD) and going-concern risk, so a standard mature-company FCF DCF is unreliable; anchoring a terminal-multiple valuation to management's own near-term revenue/profitability targets and the recently upsized, investor-validated $21M CAD financing better reflects this option-like early-commercialization stage, while a high discount rate disciplines the execution risk.